Conjugate vaccine is a combination of a weak antigen with a strong antigen so as to provide active immunization against immune system having a stronger response to the weak antigen. In a conjugate vaccine, the weak antigen is covalently attached to a strong antigen and triggers stronger immunological response to the weak antigen. The weak antigen is a polysaccharide that is attached to strong protein antigen.
Conjugate vaccines target several leading causes of vaccine-preventable deaths. Advantages of conjugate vaccines include their ability to elicit immunological memory and to reduce asymptomatic carriage of the bacteria, resulting in marked herd immunity. These vaccines offer immunization from different bacterial strains. For instance, on January 24, 2022 according to the Centers for Disease Control and Prevention (CDC) April 2019 data, pneumococcal conjugate vaccine (called PCV13) protects against 13 types of pneumococcal bacteria. Whereas in 2021, US FDA (Food and Drug Administration) licensed PCV15 and PCV20 for use in adults 18 years or older. Clinical trial data showed that PCV15 and PCV20 caused the body’s immune system to create antibodies, which helped fight the pneumococcal bacteria, similar to PCV13.
Market Dynamics
Increasing prevalence of pneumonia cases are expected to drive growth of the global conjugate vaccine market over the forecast period. For instance, in August 2021, National Center for Biotechnology Information, published a report on Community-Acquired Pneumonia, which reported that the estimated worldwide incidence of community-acquired pneumonia varies between 1.5 to 14 cases per 1000 person-years, and this is affected by geography, season, and population characteristics. In the U.S., the annual incidence is 24.8 cases per 10,000 adults with higher rates as age increases, whereas the mortality rate is as high as 23% for patients admitted to the intensive care unit.
Increasing initiatives taken by the governments of countries to launch new vaccines are expected to drive growth of the global conjugate vaccine market over the forecast period. For instance, in October 2021, Union Health Minister (India), Dr. Mansukh Mandaviya, launched a nationwide expansion of Pneumococcal 13-valent Conjugate Vaccine (PCV) under the Universal Immunization Programme (UIP) as a part of Azadi ka Amrit Mahotsav. Whereas, on the other hand communication and awareness packages on PVC were also made available in India.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Detailed Segmentation:
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients